Evaluate, a data, insight and intelligence provider to the life sciences industry, agreed to merge with MMIT, a trusted, go-to-market partner that provides a platform, insights, and consulting services to move lifesaving therapies from pipeline to patients, in a $1.6bn deal. "MMIT and Evaluate share a mission of helping patients get access to lifesaving therapies. As customers’ decision-making processes become increasingly more centralized, we couldn’t be more thrilled to come together and offer a comprehensive solution for bringing new drugs to market and to patients," Mike Gallup, MMIT CEO.